We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$385M
AUM Growth
-$76.2M
Cap. Flow
-$70.4M
Cap. Flow %
-18.28%
Top 10 Hldgs %
44.6%
Holding
124
New
35
Increased
20
Reduced
21
Closed
33

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$16.8M
2
LLY icon
Eli Lilly
LLY
+$15.1M
3
SHPG
Shire pic
SHPG
+$13.7M
4
AMGN icon
Amgen
AMGN
+$13.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.79M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.6M
2
BIIB icon
Biogen
BIIB
+$18M
3
ORA icon
Ormat Technologies
ORA
+$13.3M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.65M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.41M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Technology 4.38%
3 Communication Services 1.71%
4 Consumer Discretionary 1.16%
5 Financials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMX
76
DELISTED
Terminix Global Holdings, Inc.
TMX
$1.1M 0.29%
+41,431
New +$1.05M
ABUS icon
77
Arbutus Biopharma
ABUS
$857M
$1.04M 0.27%
300,000
-154,500
-34% -$654K
DARE icon
78
Dare Bioscience
DARE
$18.3M
$954K 0.25%
+3,750
New +$1.2M
IMMU
79
DELISTED
Immunomedics Inc
IMMU
$928K 0.24%
+400,000
New +$1.34M
OTLK icon
80
Outlook Therapeutics
OTLK
$183M
$881K 0.23%
+1,619
New +$966K
HZNP
81
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$823K 0.21%
+50,000
New +$809K
MRTX
82
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$819K 0.21%
+150,000
New +$2.39M
ATXS
83
DELISTED
Astria Therapeutics
ATXS
$752K 0.2%
3,387
-447
-12% -$135K
SPNS
84
DELISTED
Sapiens International
SPNS
$714K 0.19%
+60,949
New +$733K
PTN
85
Palatin Technologies
PTN
$13.7M
$448K 0.12%
812
-1,000
-55% -$633K
ABEO icon
86
Abeona Therapeutics
ABEO
$366M
$326K 0.08%
5,524
-13,198
-70% -$902K
CYTK icon
87
Cytokinetics
CYTK
$10.5B
$304K 0.08%
32,069
-309,875
-91% -$2.54M
SCYX icon
88
SCYNEXIS
SCYX
$48.1M
$279K 0.07%
1,606
-2,202
-58% -$623K
INSY
89
DELISTED
Insys Therapeutics, Inc.
INSY
$212K 0.06%
+16,407
New +$239K
OEF icon
90
PUT
iShares S&P 100 ETF
OEF
$20.1B
$200K 0.05%
2,000
-248,000
-99% -$22.9M
ELLO icon
91
Ellomay Capital Ltd
ELLO
$270M
$43K 0.01%
5,653
– –
ACAD icon
92
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-150,000
Closed -$4.19M
ACAD icon
93
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-80,000
Closed -$2.24M
AGIO icon
94
Agios Pharmaceuticals
AGIO
$1.79B
– –
-50,000
Closed -$2.03M
ALNY icon
95
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-70,000
Closed -$4.41M
APD icon
96
Air Products & Chemicals
APD
$65.7B
– –
-15,860
Closed -$2.11M
AXSM icon
97
Axsome Therapeutics
AXSM
$11.2B
– –
-109,069
Closed -$938K
CPRX
98
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-905,000
Closed -$1.06M
ESLT icon
99
Elbit Systems
ESLT
$37.9B
– –
-34,456
Closed -$3.24M
FOLD
100
PUT
DELISTED
Amicus Therapeutics
FOLD
– –
-300,000
Closed -$2.54M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sphera Funds Management held 124 positions worth $385M, down 17% from $461M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management withdrew a net $70.4M in Q2 2016, closing 33 positions and reducing 21 holdings. Its most notable exit was Ormat Technologies, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 62% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in GSK worth $6.39M.

  • Sphera Funds Management's largest Q2 2016 buy was GSK: 318,630 shares worth $6.39M.
  • Sphera Funds Management added most to Shire pic in Q2 2016, an estimated $13.7M increase.
  • Sphera Funds Management's biggest Q2 2016 reduction was Pfizer, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited Ormat Technologies in Q2 2016, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $385M portfolio in Q2 2016.
  • Sphera Funds Management opened 35 new positions and closed 33 in Q2 2016.
  • Sphera Funds Management's portfolio value fell 17% quarter-over-quarter to $385M.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.